• 1
    Thomas J,Wang L,Clark RE,Pirmohamed M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004; 104: 37393745.
  • 2
    White DL,Saunders VA,Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697704.
  • 3
    White DL,Saunders VA,Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 40644072.
  • 4
    Crossman LC,Druker BJ,Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005; 106: 11331134.
  • 5
    Wang L,Giannoudis A,Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258264.
  • 6
    Bazeos A,Marin D,Gerrard G, et al. BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML. ASH Annu Meet Abstr 2009; 114: 3248.
  • 7
    Engler JR,Frede A,Zannettino ACW, et al. Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. ASH Annu Meet Abstr 2008; 112: 196.
  • 8
    Jiang X,Zhao Y,Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926935.
  • 9
    Labussiere H,Hayette S,Chabane K, et al. Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib. ASH Annu Meet Abstr 2008; 112: 2643.
  • 10
    Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 24742486.
  • 11
    Gabert J,Beillard E,Van Der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer program. Leukemia 2003; 17: 23182357.